Oregon Public Employees Retirement Fund increased its position in Catalent Inc (NASDAQ:CTLT) by 4.4% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 44,494 shares of the company’s stock after buying an additional 1,889 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Catalent were worth $1,562,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. Flinton Capital Management LLC boosted its stake in shares of Catalent by 17.7% in the first quarter. Flinton Capital Management LLC now owns 3,616 shares of the company’s stock worth $102,000 after buying an additional 544 shares in the last quarter. Meadow Creek Investment Management LLC raised its position in Catalent by 17.7% in the first quarter. Meadow Creek Investment Management LLC now owns 4,972 shares of the company’s stock worth $141,000 after buying an additional 748 shares during the last quarter. Acadian Asset Management LLC raised its position in Catalent by 115.7% in the first quarter. Acadian Asset Management LLC now owns 5,847 shares of the company’s stock worth $166,000 after buying an additional 3,136 shares during the last quarter. Forward Management LLC raised its position in Catalent by 6.6% in the first quarter. Forward Management LLC now owns 5,844 shares of the company’s stock worth $166,000 after buying an additional 363 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its position in Catalent by 66.5% in the first quarter. PNC Financial Services Group Inc. now owns 6,070 shares of the company’s stock worth $173,000 after buying an additional 2,425 shares during the last quarter.
Shares of Catalent Inc (NASDAQ CTLT) traded down 0.43% on Wednesday, reaching $34.48. The company’s stock had a trading volume of 559,632 shares. The firm’s 50 day moving average is $35.81 and its 200-day moving average is $31.53. The stock has a market cap of $4.31 billion and a P/E ratio of 40.61. Catalent Inc has a 52-week low of $21.83 and a 52-week high of $38.73.
TRADEMARK VIOLATION WARNING: “Oregon Public Employees Retirement Fund Increases Position in Catalent Inc (CTLT)” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://sportsperspectives.com/2017/08/10/catalent-inc-ctlt-shares-bought-by-oregon-public-employees-retirement-fund-updated.html.
A number of research firms recently weighed in on CTLT. William Blair raised Catalent from a “market perform” rating to an “outperform” rating in a report on Friday, May 5th. Bank of America Corporation reissued a “buy” rating and set a $37.00 target price (up from $32.00) on shares of Catalent in a report on Wednesday, May 17th. Zacks Investment Research raised Catalent from a “hold” rating to a “buy” rating and set a $32.00 target price on the stock in a report on Tuesday, April 11th. BidaskClub lowered Catalent from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Finally, TheStreet raised Catalent from a “c” rating to a “b-” rating in a report on Wednesday, April 19th. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. Catalent currently has a consensus rating of “Buy” and a consensus price target of $32.00.
In other Catalent news, SVP Christine Dolan sold 745 shares of the business’s stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $34.85, for a total value of $25,963.25. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.